| Literature DB >> 32476790 |
Yue Li1, Lei Li1, Hong-Lei Weng2, Roman Liebe3, Hui-Guo Ding4.
Abstract
BACKGROUND: Computed tomography (CT), liver stiffness measurement (LSM), and magnetic resonance imaging (MRI) are non-invasive diagnostic methods for esophageal varices (EV) and for the prediction of high-bleeding-risk EV (HREV) in cirrhotic patients. However, the clinical use of these methods is controversial. AIM: To evaluate the accuracy of LSM, CT, and MRI in diagnosing EV and predicting HREV in cirrhotic patients.Entities:
Keywords: Esophageal varices; Liver cirrhosis; Liver stiffness measurement; Magnetic resonance imaging; Meta-analysis; Multidetector computed tomography imaging
Mesh:
Year: 2020 PMID: 32476790 PMCID: PMC7235201 DOI: 10.3748/wjg.v26.i18.2247
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Figure 1Flow chart of the search and selection of articles. A: Flow chart of the search and selection of articles about liver stiffness measurement; B: Flow chart of the search and selection of articles about computed tomography; C: Flow chart of the search and selection of articles about magnetic resonance imaging.
Characteristics of articles using computed tomography imaging to diagnose esophageal varices
| Cansu et al[ | Prospective | 50 | 56.8 | 54 | HBV (40.0); HCV (30.0); Biliary (6.0); HBV + HCV (4.0); Alcohol (4.0%); Others (16.0) | A (52.0); B (36.0); C (12.0) | 16-slice | Within 4 wk | 33 | 2 | 0 | 15 |
| Prospective | 42 | 56.2 | 69 | HBV (45.2); HCV (23.8); Alcohol (4.8); HBV + HCV (2.4); Biliary (2.4); Others (21.4) | A (38.1); B (31.0); C (31.0) | 16-slice | Within 4 wk | 25 | 3 | 8 | 6 | |
| Deng et al[ | Retrospective | 52 | 55.4 | 63.5 | Alcohol (30.8); HBV (25.0); HBV + Alcohol (9.6); HCV (3.8); HBV + HCV (1.9); Others (28.9) | A (49.0); B (39.2); C (11.8) | NR | NR | 43 | 2 | 2 | 5 |
| Desso-uky et al[ | Prospective | 137 | 58.7 | 53.3 | HCV (67.9); HBV (19.7); HBV + HCV (10.2); Steatohepatitis (2.2) | A (55); B (31); C (14) | 16-slice | Within 24 h | 89 | 1 | 1 | 46 |
| Elalfy et al[ | Retrospective | 124 | 56.5 | 52 | HCV (100) | A (62.9); B (37.1) | 16-slice | NR | 70 | 4 | 4 | 46 |
| Elkammash et al[ | NR | 112 | 51.4 | 68.8 | HBV (46); HCV (44); Schisto-somiasis (10) | NR | 64-slice | Within 2 wk | 97 | 0 | 2 | 13 |
| 99 | 0 | 0 | 13 | |||||||||
| Jiang et al[ | NR | 89 | 57 | 64 | HBV (71.9); Alcohol (11.2); HCV (7.9); Biliary (5.6); Drug (1.1); Unknown (2.3) | NR | 64-slice | NR | 58 | 3 | 8 | 20 |
| Kim et al[ | Retrospective | 104 | 59 | 74 | HBV (72.1); HCV (12.5); Alcohol (6.7); Others (8.7) | A (41.3); B (30.8); C (27.9) | 16 or 64-slice | Within 4 wk | 180 | 9 | 8 | 11 |
| 169 | 9 | 19 | 11 | |||||||||
| 172 | 15 | 16 | 5 | |||||||||
| Kim et al[ | Prospective | 90 | 54.8 | 72.2 | HBV (73.3); HCV (21.1); Alcohol (2.2); Others (3.3) | A (81.1); B (18.9) | 16-slice | Within 4 h | 50 | 15 | 3 | 22 |
| 47 | 12 | 6 | 25 | |||||||||
| 46 | 13 | 7 | 24 | |||||||||
| 46 | 8 | 7 | 29 | |||||||||
| Kim et al[ | Retrospective | 67 | 56.2 | 58.2 | HCV (35.8); HBV (22.4); Alcohol (22.4); HBV + HCV (9.0); Others (10.4) | A (23.9); B (37.3); C (38.8) | NR | Within 4 wk | 29 | 6 | 13 | 19 |
| 27 | 3 | 15 | 22 | |||||||||
| Lipp et al[ | Retrospective | 299 | 55.2 | 64.9 | NR | NR | 4 or 16 or 64-slice | Within 12 wk | 54 | 24 | 7 | 52 |
| 41 | 17 | 30 | 77 | |||||||||
| Moftah et al[ | NR | 54 | 56.8 | 74.1 | NR | NR | 8-slice | NR | 48 | 0 | 2 | 4 |
| Perri et al[ | Retrospective | 101 | NR | 63.4 | Viral (21.8); Alcohol (18.8); Biliary (17.8); NASH (14.9); Others (26.7) | A (44.6); B (39.6); C (15.8) | 4-slice or higher | 2 d | 73 | 10 | 6 | 12 |
| 68 | 12 | 11 | 10 | |||||||||
| Wu et al[ | Prospective | 50 | 57.7 | 60 | HBV (76); Autoimmune (2); Others (22) | A (26.0); B (62.0); C (12.0) | 16-slice | Within 4 wk | 39 | 3 | 2 | 6 |
| 40 | 5 | 1 | 4 | |||||||||
| Yu et al[ | Retrospective | 109 | 55.9 | 55 | HCV (46.8); Alcohol (17.4); HBV (6.4); Others (29.4) | NR | 16 or 64-slice | NR | 50 | 10 | 12 | 37 |
| 50 | 12 | 12 | 35 | |||||||||
| 49 | 24 | 13 | 23 | |||||||||
| 47 | 17 | 15 | 30 | |||||||||
| Zhao et al[ | Retrospective | 143 | 52.39 | 67.1 | HBV (70.6); Alcohol (11.2); Autoimmune (4.9); HCV (3.5); Biliary (3.5); Others (6.3) | A (37.8); B (33.6); C (28.7) | 64-slice | 3.4 d | 11 | 3 | 1 | 27 |
| 2 | ||||||||||||
| Zhu et al[ | Retrospective | 127 | 45.2 | 75.6 | HBV (74.8); Alcohol (10.2); HCV (4.7); Others (10.2) | A (37.8); B (37.0); C (25.2) | 4-slice | Within 4 wk | 72 | 15 | 14 | 26 |
| 67 | 11 | 19 | 30 | |||||||||
Median.
Mean. NR: Not reported; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NASH: Nonalcoholic steatohepatitis; CT: Computed tomography; EV: Esophageal varices; TP: True positive; FP: False positive; FN: False negative; TN: True negative.
Characteristics of articles using computed tomography imaging to predict HREV
| Deng et al[ | Retrospective | 52 | 55.4 | 64 | Alcohol (30.8); HBV (25.0); HBV + Alcohol (9.6); HCV (3.8); HBV + HCV (1.9); Others (28.9) | A (49.0); B (39.2); C (11.8) | NR | EVD 3.9 | NR | 35 | 4 | 4 | 9 | |
| Dessouky et al[ | Prospective | 137 | 58.7 | 53 | HCV (67.9); HBV (19.7); HBV + HCV (10.2); Steato-hepatitis (2.2) | A (55); B (31); C (14) | 16-slice | EVD 3.0 | Within 24 h | 38 | 0 | 0 | 99 | |
| Elalfy et al[ | Retrospective | 124 | 56.5 | 52 | HCV (100) | A (62.9); B (37.1) | 16-slice | PVD 12.5 | NR | 33 | 49 | 13 | 29 | |
| Kim et al[ | Retrospective | 110 | 61 | 74 | HBV (60.9); HCV (29.1) Alcohol (6.4); HBV + HCV (1.8); Others (1.8) | A (63.6); B (26.4); C (10.0) | 16-slice | EVD 2.0 | 8.2 d | 123 | 15 | 9 | 61 | |
| 113 | 2 | 19 | 59 | |||||||||||
| 115 | 15 | 17 | 61 | |||||||||||
| Kim et al[ | Retrospective | 104 | 59 | 74 | HBV (72.1); HCV (12.5); Alcohol (6.7); Others (8.7) | A (41.3); B (30.8); C (27.9) | 16 or 64-slice | EVD 2.0 | Within 4 wk | 34 | 3 | 3 | 70 | |
| 36 | 10 | 1 | 63 | |||||||||||
| 32 | 4 | 5 | 69 | |||||||||||
| Kim et al[ | Prospective | 90 | 54.8 | 72 | HBV (73.3); HCV (21.1); Alcohol (2.2); Others (3.3) | A (81.1); B (18.9) | 16-slice | Grade 2 and Grade 3 | Within 4 h | 28 | 11 | 2 | 49 | |
| 28 | 5 | 2 | 55 | |||||||||||
| 27 | 9 | 3 | 51 | |||||||||||
| 27 | 2 | 3 | 58 | |||||||||||
| Kim et al[ | Retrospective | 67 | 56.2 | 58 | HCV (35.8); HBV (22.4); Alcohol (22.4); HBV + HCV (9.0); Others (10.4) | A (23.9); B (37.3); C (38.8) | NR | EVD 3.0 | Within 4 wk | 11 | 9 | 1 | 46 | |
| 11 | 9 | 1 | 46 | |||||||||||
| Lipp et al[ | Retrospective | 299 | 55.2 | 65 | NR | NR | 4 or 16 or 64-slice | EVD 4.0 | Within 12 wk | 18 | 11 | 12 | 96 | |
| 12 | 4 | 22 | 127 | |||||||||||
| Perri et al[ | Prospective | 101 | NR | 63 | Viral (21.8); Alcohol (18.8); Biliary (17.8); NASH (14.9); Others (26.7) | A (44.6); B (39.6); C (15.8) | 4-slice or higher | EVD 5.0 | 2 d | 23 | 5 | 18 | 55 | |
| 27 | 8 | 14 | 52 | |||||||||||
| Yu et al[ | Retrospective | 109 | 55.9 | 55 | HCV (46.8); Alcohol (17.4); HBV (6.4); Others (29.4) | NR | 16 or 64-slice | EVD 2.0 | NR | 25 | 24 | 1 | 59 | |
| 25 | 18 | 1 | 65 | |||||||||||
| 23 | 41 | 3 | 42 | |||||||||||
| 23 | 17 | 3 | 66 | |||||||||||
Mean.
Median.
Grade 2: Varices show beaded appearance; Grade 3: Varices run in oblique course and are tortuous with tumorlike appearance. EVD: Esophageal varices diameter; NR: Not reported; PVD: Portal vein diameter; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NASH: Nonalcoholic steatohepatitis; CT: Computed tomography; HREV: High-bleeding-risk esophageal varices; TP: True positive; FP: False positive; FN: False negative; TN: True negative.
Figure 2Methodological evaluation according to Quality Assessment of Diagnostic Accuracy Studies-2 of the included articles. A, C, and E: Diagnosis of esophageal varices using liver stiffness measurement, computed tomography, and magnetic resonance imaging, respectively; B, D, and F: Prediction of high-bleeding-risk esophageal varices using liver stiffness measurement, computed tomography, and magnetic resonance imaging, respectively. Articles were identified as having a potential bias risk for patient selection and index text.
Overview of results of meta-analysis
| Diagnostic threshold | ||||||
| Spearman correlation coefficient | 0.36 | 0.21 | -0.2 | 0.12 | 0.27 | 0.57 |
| 0.19 | 0.5 | 0.27 | 0.58 | 0.56 | 0.11 | |
| SROC | ||||||
| AUSROC (95%CI) | 0.86 (0.83-0.89) | 0.85 (0.81-0.88) | 0.91 (0.88-0.93) | 0.94 (0.91-0.96) | 0.86 (0.83-0.89) | 0.83 (0.79-0.86) |
| 97.43% | 97.13% | 97.17% | 98.30% | 86.41% | 91.64% | |
| < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | |
| Sensitivity | ||||||
| Summary sensitivity (95%CI) | 0.84 (0.78-0.89) | 0.81 (0.75-0.86) | 0.91 (0.87-0.94) | 0.88 (0.82-0.92) | 0.81 (0.76-0.86) | 0.80 (0.72-0.86) |
| 82.63% | 70.93% | 88.46% | 87.06% | 33.57% | 67.03% | |
| < 0.01 | < 0.01 | < 0.01 | < 0.01 | 0.17 | < 0.01 | |
| Specificity | ||||||
| Summary specificity (95%CI) | 0.71 (0.60-0.80) | 0.73 (0.66-0.80) | 0.75 (0.68-0.82) | 0.87 (0.81-0.92) | 0.82 (0.70-0.89) | 0.72 (0.62-0.80) |
| 86.56% | 91.65% | 80.58% | 93.26% | 74.53% | 83.17% | |
| < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | |
| PLR | ||||||
| Summary PLR (95%CI) | 2.91 (2.08-4.06) | 3.04 (2.38-3.89) | 3.67 (2.73-4.94) | 6.90 (4.54-10.49) | 4.44 (2.74-7.21) | 2.83 (2.11-3.80) |
| 82.66% | 85.63% | 83.81% | 91.04% | 31.66% | 51.94% | |
| < 0.01 | < 0.01 | < 0.01 | < 0.01 | 0.01 | < 0.01 | |
| NLR | ||||||
| Summary NLR (95%CI) | 0.22 (0.16-0.30) | 0.26 (0.19-0.34) | 0.12 (0.08-0.18) | 0.14 (0.09-0.21) | 0.23 (0.18-0.28) | 0.28 (0.21-0.38) |
| 79.49% | 68.30% | 88.94% | 91.10% | <0.01% | 43.01% | |
| < 0.01 | < 0.01 | < 0.01 | < 0.01 | 0.53 | 0.08 | |
| Summary DOR (95%CI) | 13.01 (7.83-21.64) | 11.93 (7.89-18.03) | 30.98 (16.02-59.91) | 49.99 (25.38-98.43) | 19.58 (11.39-33.66) | 10.00 (6.63-15.09) |
A significant heterogeneity was found in all analyses. There were no threshold effects in all analyses (P > 0.05). CT had the largest area under the summary receiver operating characteristic curves in both of the diagnosis of EV and prediction of HREV. SROC: Summary receiver operating characteristic curves; CT: Computed tomography; EV: Esophageal varices; HREV: High bleeding risk esophageal varices; MRI: Magnetic resonance imaging; LSM: Liver stiffness measurement; PLR: Positive likelihood ratio; NLR: Negative likelihood ratio; DOR: Diagnostic odds ratio; AUSROC: Area under the summary receiver operating characteristic curves.
Figure 3Summary receiver operating characteristic curves. A and B: Summary receiver operating characteristic (SROC) curves of liver stiffness measurement, computed tomography, and magnetic resonance imaging for the diagnosis of esophageal varices (EV) and prediction of high-bleeding-risk EV (HREV); C and D: SROC curves of liver stiffness measurement for the diagnosis of EV and prediction of HREV; E and F: SROC curves of computed tomography for the diagnosis of EV and prediction of HREV; G and H: SROC curves of magnetic resonance imaging for the diagnosis of EV and prediction of HREV.
Figure 4Summary sensitivity and specificity of liver stiffness measurement. A and B: Summary sensitivity and specificity of liver stiffness measurement for the diagnosis of esophageal varices; C and D: Summary sensitivity and specificity of liver stiffness measurement for the prediction of high-bleeding-risk esophageal varices.
Figure 5Summary sensitivity and specificity of computed tomography imaging. A and B: Summary sensitivity and specificity of computed tomography for the diagnosis of esophageal varices; C and D: Summary sensitivity and specificity of computed tomography imaging for the prediction of high-bleeding-risk esophageal varices.
Figure 6Summary sensitivity and specificity of magnetic resonance imaging. A and B: Summary sensitivity and specificity of magnetic resonance imaging for the diagnosis of esophageal varices; C and D: Summary sensitivity and specificity of magnetic resonance imaging for the prediction of high-bleeding-risk esophageal varices.